Diane Nugent, MD
Pediatric Hematology-Oncology · Orange, CANPI 1770528663
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (31.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Novo Nordisk Health Care AG at 45.8% of the total. Reporting peaked in 2019 at $34,900 and has fallen 99.0% since, to $364 in 2025. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $1136.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk Health Care AG$25K
- Biomarin Pharmaceutical Inc.$13K
- Novo Nordisk$10K
- Dova Pharmaceuticals$3K
- CSL Behring$3K
- Genentech USA, Inc.$166
- plus $513 from 8 others
Across 20 payments — averaging $29,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$501K
- Novo Nordisk AS$97K
What the payments were for
- Consulting fees$12,43023%
- Speaking & faculty fees$13,52325%
- Travel & lodging$17,23832%
- Food & beverage$11,34421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk Health Care AG | 7 | $24,980 |
| Biomarin Pharmaceutical Inc. | 8 | $12,607 |
| Novo Nordisk | 13 | $10,479 |
| Dova Pharmaceuticals | 1 | $3,080 |
| CSL Behring | 1 | $2,710 |
| Genentech USA, Inc. | 4 | $166 |
| Novartis | 3 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $126 |
| Blueprint Medicines Corporation | 1 | $120 |
| Sanofi | 1 | $36 |
| Vertex | 1 | $28 |
| Qiagen, LLC | 1 | $22 |
| Bayer | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,535 in reported general payments places this provider in the 90th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium ChlorideSodium Chloride 0.45 % | 13 | $414 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Orange
- Vanessa Salinas-LunaOrange$344K
- Arash MahajerinOrange$249K
- Amit SoniOrange$70K
- Esteban GomezOrange$56K
- van HuynhOrange$37K
- Mariko SatoOrange$21K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.